MiNK Therapeutics, Inc. INKT
- agenT-797 — Acute Respiratory Distress Syndrome Phase 2
- agenT-797 — Solid Tumors Phase 1
- agenT-797 — Gastric Cancer Phase 2
- agenT-797 — Graft-Versus-Host Disease Phase 1
CD1d (1 companies · 4 programs)
Companies with an active program directed at CD1d.